This research, posted in JAMA, looked to find the optimal duration of antibiotic treatment in patients with community-acquired pneumonia. In this randomized clinical trial that included 312 patients, the clinical success rate was 50.4% in the control and 59.7% in the intervention group at day 10 and 92.6% in controls and 94.4% in the intervention group at day 30 without significant differences. Clinical success rate at day 10 and late follow-up (day 30) since admission, defined as resolution or improvement in signs and symptoms related to pneumonia without the use of additional antibiotics, and CAP-related symptoms at day 10 measured with the 18-item CAP symptom questionnaire, were the primary outcomes. The community-acquired pneumonia symptom questionnaire scores at days 5 and 10 were similar between the groups. In terms of clinical success, this study shows that stopping antibiotic treatment based on clinical stability criteria after a minimum of 5 days of suitable treatment is not inferior to typical treatment schedules. The study concluded that basing antibiotic treatment duration on clinical stability criteria leads to a significant reduction in treatment duration without increasing the rate of adverse outcomes.